FUTURE / EXPLORATION

下一步，
从证据出发。The next step
starts with evidence.

我们正审慎、合规、分阶段地探索生物医药、生命科学与健康科技方向。We are exploring biopharma, life sciences and health technology prudently, compliantly and in stages.

NOW

桌面研究Desk research

跟踪方向、积累判断，不以未经验证的想象替代事实。Track directions and build judgment without substituting imagination for fact.

NEXT

小步验证Small validation

只有在资源、路径和合规边界清晰之后，才讨论下一步投入。Only discuss investment once resources, route and compliance boundaries are clear.

LATER

条件放大Earned scale

团队、资金、合作与合规就绪后，再谈规模。Scale only when team, funding, collaboration and compliance are ready.

TRACKS / EXPLORATORY

四条探索方向，只做能算清账的部分Four tracks — only what we can underwrite

以下均为探索方向，不代表现有产品、临床项目、收入或监管批准；当前所处：阶段一 · 桌面研究。Exploratory directions only — not existing products, trials, revenue or approvals. Current phase: Phase 1 · desk research.

01 · EXPLORATORY

精准医疗 — 先分层，再谈投入Precision medicine — segment first, fund later

先把人群、适应症与支付意愿算清楚，再谈投不投。Size the population, indication and willingness to pay before committing.

  • 适应症与人群规模、支付意愿测算Indication sizing and willingness-to-pay analysis
  • 竞品格局与差异化窗口判断Competitive landscape and differentiation windows
  • 进入 / 放弃的量化门槛，花钱前先写好Go / no-go thresholds, written before spending
02 · EXPLORATORY

细胞与免疫 — 长周期，先算资金账Cell & immuno — fund the long cycle first

先拆里程碑、再排融资节奏，不一次投入。Milestone budgets and financing rhythm — never all-in upfront.

  • 按里程碑拆解成本与风险敞口Milestone-based cost and exposure breakdown
  • 融资节奏与现金流安全垫Financing cadence and cash cushions
  • 每阶段退出标准，事先约定Pre-agreed exit criteria at every gate
03 · EXPLORATORY

人工智能辅助研发 — 工具提效，判断守规AI-assisted R&D — tools for speed, evidence for calls

AI 负责初筛与提效，关键结论经人工证据复核。AI handles triage and acceleration; key calls pass human evidence review.

  • 文献、靶点、数据三类初筛Literature, target and data triage
  • 研发流程提效降本测算Measurable efficiency and cost gains
  • 不承诺疗效，结论可复核No promises on efficacy; conclusions reviewable
04 · EXPLORATORY

项目孵化 — 小步验证，分段给钱Incubation — prove small, fund in stages

可行性过会 → 小规模验证 → 条件具备再放大。Feasibility gate, small validation, scale-up only when earned.

  • 立项可行性门槛与过会标准Feasibility thresholds and review standards
  • 小规模验证指标与周期Small-scale validation metrics and timelines
  • 放大条件与止损线Scale-up conditions and stop-loss lines
联系 CPL →Contact CPL →讨论探索方向 →Discuss these tracks →
BOUNDARY

不夸大承诺No inflated claims

本页为探索方向，不代表现有产品、临床项目、收入或监管批准。These are exploratory directions, not existing products, trials, revenue or approvals.

DISCLOSURE

前瞻性陈述Forward-looking statements

本页关于未来的表述属前瞻性陈述，实际结果可能因市场、资金、团队、合作与监管等因素产生重大差异；公司尚未对任何产品、技术、审批、融资或回报作出保证，不构成证券发行、投资建议或收益承诺。Forward-looking statements here may differ materially with market, funding, team, partnership and regulatory factors; no guarantee on products, technology, approvals, financing or returns, and nothing herein is a securities offer, investment advice or return commitment.